Physician profile
Shea S Fleming
NPI 1063585636
$2,585.82
in general payments reported to CMS, 2019-2025
20 companies · $240 in 2025
The $240 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.64 · 2020: $53.47 · 2021: $1,521 · 2022: $290 · 2023: $205 · 2024: $210 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634 · Long Term Medical Supply Or Device Loan: $20.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.34 |
| Long Term Medical Supply Or Device Loan | $20.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,250.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $207.96 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $193.10 | 2021-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $169.07 | 2021-2022 | |
| Corium, LLC | $113.33 | 2022-2025 | Azstarys |
| Pfizer INC. | $86.20 | 2022-2025 | |
| Glaxosmithkline, LLC. | $69.47 | 2019-2025 | Bexsero |
| Merck Sharp & Dohme LLC | $68.99 | 2019-2022 | |
| Kaleo, INC. | $65.76 | 2020-2023 | Auvi-Q |
| Biomarin Pharmaceutical INC. | $52.85 | 2025 | Voxzogo 1.2mg |
| Adlon Therapeutics L.P. | $48.98 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $46.67 | 2024 | Ycanth |
| Cranial Technologies, INC | $37.36 | 2022 | |
| Seqirus USA INC | $35.83 | 2024-2025 | Flucelvax |
| Baxter Healthcare | $33.01 | 2019-2024 | Hillrom - Spot Vital Signs 4400 Device |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.77 | 2019 | |
| Lnhc, INC | $26.51 | 2025 | Zelsuvmi |
| Astrazeneca Pharmaceuticals Lp | $20.99 | 2025 | |
| Ironshore Pharmaceuticals INC. | $15.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.